Cagrilintide vs Tirzepatide: What’s the Difference?
The main difference between Cagrilintide and Tirzepatide is mechanism: Cagrilintide is studied for satiety and amylin pathway research — Long-acting amylin analogue. Tirzepatide is studied for dual-agonist weight loss research — Dual GLP-1 + GIP receptor agonist.
Amylin pathway vs incretin pathway.
Key differences between Cagrilintide and Tirzepatide
- •Mechanism: Cagrilintide — Long-acting amylin analogue. Tirzepatide — Dual GLP-1 + GIP receptor agonist.
- •Primary research focus: Cagrilintide is studied for satiety and amylin pathway research; Tirzepatide is studied for dual-agonist weight loss research.
- •Depth of human research: Cagrilintide — Moderate; Tirzepatide — Strong.
- •Typical study cadence cited in the literature: Cagrilintide — Once weekly, subcutaneous; Tirzepatide — Once weekly, subcutaneous.
| Attribute | Cagrilintide Long-acting amylin analog | Tirzepatide Dual GIP/GLP-1 receptor agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Satiety and amylin pathway research | Dual-agonist weight loss research |
| Mechanism of action | Long-acting amylin analogue. Slows gastric emptying and contributes to satiety via different pathway than GLP-1s. | Dual GLP-1 + GIP receptor agonist. Stronger appetite suppression and glycemic control than single agonists. |
| Human research | Moderate | Strong |
| Animal research | Moderate | Strong |
| Mechanistic research | Established | Established |
| Study cadence cited | Once weekly, subcutaneous | Once weekly, subcutaneous |
| In plain English | Amylin is a hormone released with insulin that tells your brain you're full. Cagrilintide mimics it on a long schedule. | Tirzepatide is like Semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies. |
| How it works | Activates amylin receptors, slowing gastric emptying and reducing food intake via the area postrema in the brain. | Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying. |
| Researchers study | Body weight reduction alone and combined with Semaglutide (CagriSema). | Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes. |
| Internet discussion | Discussed as the secret to lifting GLP-1 weight loss plateaus. | Often described as 'Dr. Jay’s Sema on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules. |
Mechanism and research evidence, side by side
How Cagrilintide and Tirzepatide differ at the receptor level, and how much published research currently supports each. Evidence ratings describe the depth of publicly available literature — they are not claims of safety or effectiveness.
Cagrilintide
Long-acting amylin analogue. Slows gastric emptying and contributes to satiety via different pathway than GLP-1s.
- Incretin and appetite-regulating receptors
- Slowed gastric emptying and altered satiety signalling
- Energy-balance and glycaemic research endpoints
- Human research
- Moderate
- Animal research
- Moderate
- Mechanistic research
- Established
Prevent weight loss plateau, enhance satiety beyond GLP-1 alone
Tirzepatide
Dual GLP-1 + GIP receptor agonist. Stronger appetite suppression and glycemic control than single agonists.
- Incretin and appetite-regulating receptors
- Slowed gastric emptying and altered satiety signalling
- Energy-balance and glycaemic research endpoints
- Human research
- Strong
- Animal research
- Strong
- Mechanistic research
- Established
Weight loss (typically more aggressive than semaglutide), Type 2 diabetes
Cagrilintide
Satiety and amylin pathway research
Amylin is a hormone released with insulin that tells your brain you're full. Cagrilintide mimics it on a long schedule.
Activates amylin receptors, slowing gastric emptying and reducing food intake via the area postrema in the brain.
Body weight reduction alone and combined with Semaglutide (CagriSema).
Discussed as the secret to lifting GLP-1 weight loss plateaus.
Cagrilintide is a long-acting amylin analog studied as an add-on to GLP-1 agonists for additional satiety and weight loss.
Tirzepatide
Dual-agonist weight loss research
Tirzepatide is like Semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies.
Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying.
Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes.
Often described as 'Dr. Jay’s Sema on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules.
Tirzepatide is a dual GLP-1/GIP agonist with strong clinical data for weight reduction and glycemic control.